A protein shake being mixed, the everyday form the trial's 20 gram daily dose of soy or casein isolate took.
Shixart1985CC BY 2.0
Illustrative. Not a trial participant, not the specific soy or casein isolate used, and not the older age group the trial actually studied.
A Protein Powder Trial Found Two Glycation Markers Shifted, but Total AGEs Did Not Move
Protein powder is probably the single most used supplement among people who read this newsletter, and a question I get asked in some form almost every month is whether the type you choose matters for aging. A new trial gives a real, specific answer for the first time, and it is more reassuring than alarming, with one honest asterisk worth understanding.
- A 16 week randomized trial gave 65 older Singaporean adults 20 grams a day of soy protein isolate, casein protein isolate, or nothing extra, all on the same healthy diet.
- Soy raised one glycation marker called CML. Casein raised a different marker called pentosidine within its own group, though that second result did not hold up in the proper group comparison.
- Total circulating AGEs and skin accumulated AGEs, the measures that would actually signal a meaningful change, did not move in any group.
- This is the first randomized trial to test whether protein source changes glycation chemistry, and the honest answer is barely, in narrow ways, while the overall picture stayed reassuring.
Total and skin AGEs unchanged
In every arm, over 16 weeks, at a realistic 20 gram daily dose. This is the trial's own primary finding.
Two markers moved, in opposite arms
Soy raised plasma CML. Casein raised plasma pentosidine within its own group only, a result that did not hold up in the group comparison.
Both are true. Neither cancels the other out.
What the trial actually measured
Researchers wanted to know whether protein source changes advanced glycation end products, or AGEs, the compounds that form when proteins or fats bond with sugars in the body and that build up in tissue over a lifetime. AGEs are elevated in people with type 2 diabetes and coronary heart disease, and some researchers have wondered whether higher protein intake, a cornerstone of healthy aging advice, could quietly push glycation in the wrong direction depending on the source.
What actually happened
Sixty five adults aged 60 to 80 were randomized to control, 20 grams a day of casein protein isolate, or 20 grams a day of soy protein isolate, taken with 250 milliliters of low fat milk, for 16 weeks, all following Singapore's My Healthy Plate dietary pattern.
Soy raised plasma CML, a specific AGE marker, from an average of 0.72 up to 0.80 over the 16 weeks, a change that held up in the formal group comparison. Casein raised a different marker, plasma pentosidine, from 0.77 up to 0.80 within its own group, but that shift did not survive the same statistical test against the other groups, meaning it should not be reported as casein causing a real effect. The proposed mechanisms, soy's higher lysine content feeding CML formation and casein's slower gastric transit prolonging the window for crosslinking, were not directly measured in this trial and the authors themselves label them speculative.
Honest caveat
This trial has real limits. It was single blinded, not double blinded. Sixty five people split across three arms is small for a biomarker with high person to person variance, and the effect sizes involved are tiny in absolute terms. No clinical outcomes were measured, only blood and skin biomarkers, and nobody has shown that a shift this small over 16 weeks matters to anything a person would actually feel or experience. The trial studied one population, older adults in Singapore following a specific national dietary pattern, which limits how far the results generalize.
What this means for you
One small trial in one population is not the final word on whether protein source matters for glycation, and the honest answer here is barely, in narrow ways, with unclear consequences. If you take a daily scoop of soy or casein protein, this trial gives you no real reason to switch. The measure most likely to matter, total AGE burden, did not move in either group, and the one marker that did move in a statistically sound way, CML from soy, moved by a small amount over four months with no known health consequence demonstrated. If you are choosing between protein sources, digestion, amino acid profile, allergies and personal preference are still the more useful factors than a glycation worry this trial mostly put to rest.
the honest answer here is barely, in narrow ways, with unclear consequences
Primary sources
Common questions
Does this mean protein powder ages you?
No. The trial's own headline result is the opposite: total circulating AGEs and skin accumulated AGEs did not change in any group over 16 weeks, at a realistic 20 gram daily dose. Two individual markers moved in opposite arms, but the overall glycation burden the total measures were designed to catch did not budge.
Should I switch from soy to casein, or the other way around, because of this?
Not based on this alone. The soy result held up in the proper statistical comparison and the casein result did not, so soy has the slightly stronger signal of the two, but both effects were small and neither changed the trial's null headline finding. This is one trial in one population over 16 weeks, not grounds for switching protein sources.
Why does a null result matter enough to write about?
Because it is the first randomized trial to actually test whether protein source changes glycation chemistry in older adults, rather than assume it based on mechanism. A well designed trial that finds mostly nothing is more informative than no trial at all, and the two narrow marker moves are a real lead for future research even though they did not change the overall picture.
Stay Curious.
Better health isn't found in a single article. It's built through curiosity, evidence, and small discoveries over time. Join thousands exploring longevity, gut health, recovery, nutrition, and the tools that truly make a difference.